SCHEMBL10305109

SCHEMBL10305109

COc1ccc(C)c(-c2csc(OC)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A1 P04798 4/20 0.50
▸ CYP1B1 Q16678 4/20 0.50
▸ MEN1 O00255 5/20 0.45
▸ KMT2A Q03164 5/20 0.45
▸ NPC1 O15118 4/20 0.45
▸ CYP19A1 P11511 1/20 0.45
▸ MAPT P10636 6/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ NFKB1 P19838 2/20 0.44
▸ NFKB2 Q00653 2/20 0.44
▸ RELA Q04206 2/20 0.44
▸ ATM Q13315 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ GAA P10253 2/20 0.42
▸ THRB P10828 1/20 0.42
▸ PTGS2 P35354 1/20 0.42
▸ POLB P06746 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10304992 0.87 CYP1A1 (0.45) CYP1A1CYP1B1MEN1KMT2ANPC1
SCHEMBL10304993 0.86 MEN1 (0.51) CYP1A1CYP1B1MEN1KMT2ANPC1
SCHEMBL10304990 0.83 HSP90AA1 (0.47) CYP1A1CYP1B1MEN1KMT2ANPC1
SCHEMBL10305003 0.79 ATP4A (0.51) MEN1KMT2ANPC1CYP19A1MAPT
SCHEMBL10305108 0.78 CYP1A1 (0.42) CYP1A1CYP1B1MEN1KMT2ANPC1
SCHEMBL10305110 0.74 HSP90AB1 (0.45) CYP1A1CYP1B1NPC1MAPTRAB9A
SCHEMBL15178722 0.74 RAB9A (0.45) CYP1A1CYP1B1MEN1KMT2ANPC1
SCHEMBL10305055 0.73 ALDH1A1 (0.43) CYP1A1CYP1B1MEN1KMT2ANPC1
SCHEMBL19626481 0.72 KMT2A (0.61) CYP1A1CYP1B1MEN1KMT2ANPC1
SCHEMBL15624619 0.72 CYP1A1 (0.44) CYP1A1CYP1B1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264770-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-18 — — US disclosed
US-20120172321-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 — — US disclosed
US-20090305998-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090305998-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 CYP1A1 2326/4885CYP1B1 1917/4885MEN1 4621/4885
US-20120264770-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 CYP1A1 2326/4885CYP1B1 1917/4885MEN1 4621/4885
US-20120172321-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 CYP1A1 2326/4885CYP1B1 1917/4885MEN1 4621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback